Invitris owns a proprietary cell-free in vitro expression technology platform, PhactoryTM, to help co-develop & manufacture the next generation of proteins. We are capable of both prokaryotic and mammalian cell-free expression. Our focus areas are microbial and mammalian proteins, including bacteriophages, viruses, endolysins, tailocins, enzymes, antibodies, nanobodies, and membrane proteins. We're active in the fields of oncology, neurogenerative diseases, antibiotics, agriculture, technical industries, and more.